Stocks
QLT Technologies IncorporatedQLTX
HealthcareBiotechnology
A specialty pharmaceutical company focused on developing and commercializing therapies for eye diseases, particularly inherited retinal disorders. Its lead product, Luxturna, is a gene therapy for a rare form of blindness, making it a key player in the emerging gene therapy space. Investors track QLT for its pipeline progress and commercial execution in the ophthalmic market.
Congressional Interest in QLT Technologies Incorporated (QLTX)
1 member of Congress has disclosed 1 trade in QLT Technologies Incorporated (QLTX), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading QLTX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-04-10 | JAMES B. RENACCI | sell | $1K-$15K |